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Stlmm~'y 
Human T lymphocyte virus type I (HTLV-I) can be transmitted into several inbred strains of 
newborn and adult rats by inoculating newly established HTLV-I-immortalized rat T cell lines 
or the human T cell line MT-2.  The transmission efficiency exceeds 80%, regardless of strain 
differences or the age at transmission. The production of anti-HTLV-I  antibodies significantly 
differs among the strains and depends on the age at the time of transmission. Rats neonatally 
inoculated with HTLV-I-positive rat or human cells generally become seronegative HTLV-I carriers 
throughout their lives, whereas adult rats inoculated with HTLV-I-positive  cells at 16 wk of 
age become seropositive HTLV-I carriers.  The HTLV-I provirus genome is present in almost 
all organs, regardless of whether the carriers are seronegative or seropositive. According to antibody 
titers to HTLV-I, there are three groups of inbred rat strains: ACI, F344, and SDJ (high responders); 
WKA, BUF, and LEJ (intermediate responders); and LEW (low responder). Three of three 16- 
mo-old seronegative HTLV-I cartier rats of the WK  strain developed spastic paraparesis of the 
hind legs. Neuropathological examinations revealed that the lesions were confined primarily to 
the lateral and anterior funiculi of the spinal cord. Both myelin and axons were extensively damaged 
in a symmetrical fashion, and infiltration with massive foamy macrophages was evident. The 
most severe lesions were at levels of the thoracic cord and continued from the cervical to the 
lumbar area. These histopathological features as well as clinical symptoms largely paralld findings 
in humans with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). These 
HTLV-I carrier rats,  in particular the WKA rats described above, can serve as a useful animal 
model  for  investigating virus-host  interactions  in  the  etiopathogenesis of HTLV-I-related 
immunological diseases, particularly HAM/TSP. 
H 
'TLV-I, which was first isolated and characterized  from 
a patient with cutaneous T cell lymphoma (1), is dis- 
tinct from other human viruses and from animal retroviruses, 
in nucleic acids (2), major core proteins (3), and reverse tran- 
scriptase  (4). Further extensive study showed that HTLV-I 
is the oncogenic agent of adult T call leukemia (ATL) 1 (5). 
It was reported that HTLV-I infection is also related with 
immunological  diseases such as HTLV-I-associated  mydopathy/ 
1 Abbreviations used in this paper: ATL, adult T  cell leukemia;  BrdUrd, 
5-bromo-2'-deoxyuridine;  CNS, central nervous system; CSF, cerebrospinal 
fluid; HAM/TSP, HTLV-I-associated  myelopathy/tropical spastic parapatesis. 
tropical  spastic  paraparesis  (HAM/TSP)  (6-9),  HTLV-I- 
associated bronchopneumonopathy  (HAB) (10), HTLV-I-asso- 
dated arthropathy (HAAP) (11), and Sj6gren syndrome (12). 
To analyze mechanisms involved in the development of these 
diseases, an animal model would be useful HTLV-I has been 
reported to have immortalizing effects on human (13), simian 
(14), cat (15), and rabbit (16) lymphocytes. Yoshiki and col- 
leagues (17, 18) found that HTLV-I can infect and immor- 
talize rat T cells in vitro. Yoshiki et al. (19) and Suga et al. 
(20) suggested that HTLV-I can be transmitted into WKA 
and F344 rats in vivo. 
We have now transmitted HTLV-I into several  inbred strains 
of newborn and adult rats, and strain differences in humoral 
antibody responses  against HTLV-I and tissue distribution 
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ment of HAM/TSP-like myelopathy in HTLV-I carrier rats 
was also monitored. This is the first description of an animal 
model  for the  HAM/TSP  that  occurs in  humans￿9 
Materials and Methods 
Cell Lines.  Four HTLV-I-immortalized rat cell lines, Lewis-S1, 
WKA-S1, F344-$1,  and ACI-S1, were newly established by cocul- 
tivating  spleen cells  of four inbred  rats  of LEW/Hkm(LEW), 
WKAH/Hkm(WKA),  F344/SIc(F344),  and  ACI/Hkm(ACI) 
strains with ATL cells from a typical ATL patient after treating 
them with 5-bromo-2'-deoxyuridine (BrdUrd),  as described else- 
where (17). The cells were maintained in RPMI 1640 supplemented 
with 10% heat-inactivated FCS, penicillin(100  IU/ml), and strep- 
tomycin(100/zg/ml),  and were free from exogenous I1.-2. 
The HTLV-I producer human cell line, MT-2, was kindly provided 
by Dr. I. Miyoshi (Department of Medicine, Kochi Medical Col- 
lege, Kochi, Japan) (13). 
Antibodies.  RTH-7,  R1-3B3,  and R1-10B5  were mAbs that 
reacted with the rat homologues of CD4, CD5, and CDS, respec- 
tively, and were generously provided by Drs. A, Matsuura and K. 
Kikuchi (Sapporo Medical College, Sapporo, Japan) (21, 22). Anti- 
Leu-3a (Becton Dickinson & Co., Mountain View, CA) and ART 
18 (23) (Boehringer Mannheim, Mannheim, Germany) were the 
mAbs used against human CD4 and rat IL-2 receptor, respectively. 
Polyclonal antibodies against rat and human Ig were purchased from 
Organon Teknika Co.  (Durham,  NC). 
Animals  and  Transmission of HTLV-I.  Inbred female WKA, 
LEW,  ACI, SDJ/Hkm(SDJ),  BUF/Hkm(BUF),  and LEJ/Hkm 
(LEJ) rats were obtained from the Institute for Animal Experiment 
(Hokkaido University School of Medicine,  Sapporo, Japan). Inbred 
female F344 rats were purchased from SLC Japan (Shizuoka, Japan). 
107  Lewis-S1  and  WKA-S1  cells,  which  were  treated  with 
Mitomycin C (MMC; Kyowa Hakko, Co., Tokyo, Japan), at a con- 
centration of 25 rag/m1 for 30 min at 37~  were inoculated into 
the peritoneal cavity of newborn LEW and WKA rats within 24 h 
after birth, respectively.  107 MT-2 cells were inoculated into the 
peritoneal cavity of newborn LEW, WKA,  F344,  and ACI rats 
within 24 h after birth. 107 MT-2 cells were injected into the tail 
vein of 16-wk-old LEW, WKA, F344, ACI, SDJ, BUF, and LEJ 
rats twice, at 2-wk intervals.  HTLV-I-infected rats were maintained 
under the P3 level. 
To identify the anti-HTLV-I antibody and HTLV-I provirus ge- 
home, peripheral blood was taken from the tail vein. 
Detection of Antibodies against HTLV-I Antigens.  The titer of 
antibody against HTLV-I antigens in the serum and cerebrospinal 
fluid (CSF) was determined by the particle agglutination test (Serodia 
￿9 HTLV-I; Fuji Rebio Inc., Tokyo, Japan). 
Polyraerase Chain Reaction.  DNA was isolated from Ficoll-Paque 
separated PBMC  or organ  tissues  using SDS  and proteinase K 
methods (24). PCR was carried out as described (25). Briefly, 0.5 
#g of extracted DNA was subjected to 35 cycles of PCR amplifica- 
tion using Taq polymerase (Takara Shuzo Co.,  Kyoto, Japan) at 
94~  for 1 min, 58~  for 2 rain, and 72~  for 3 min. The primers 
were  5'-2328  GCCAAACCCAAGATCACTTTAAGC  2351-3' 
(sense) and 3'-2588 GGAAATTTGGTCTTGCGGAG 2607-5' (an- 
tisense)  for 10ol region amplification (Synthetic Genetics Inc., San 
Diego, CA), and 5'-7358 CGGATACCCAGTCTACGTGT 7377-3' 
(sense) and 3'-7516 GCTACC'IGCGCAATAGCCGAG 7496-5' (an- 
tisense) for pX region amplification (26). Each PCR product was 
subjected to electrophoresis on a 2% agarose gel and transferred 
to nylon membrane. The membrane was hybridized with radioac- 
tively hbeled oligonucleotide probes: 3'-2498 CGTTTTCCCGGC- 
GGACATTAGAACGGTTATGTCCGCGGTC  2537-5' (antisense) 
for pol region and 3'-7447 AGGTGATCTGATGCTCTGGACAG- 
GTGGCCAGTAGC~CG 7486-5' (antisense) for pX region. The 
membrane was washed in 2x  SSC, 0.2%  SDS at room tempera- 
ture for 15 min, twice, and in 0.2x  SSC, 0.2% SDS at 55~  for 
15 rain, twice. The specific amplified bands were detected by ex- 
posure to Kodak XAK film at  -70~  For the standard control, 
the detection limit of the PCK was up to 5-6. 
Light Microsco~.  In addition to routine hematoxylin and eosin 
(HE) stain, Luxol fast blue (LFB), Bodian, and Holzer stains were 
used. 
Results 
Characterization of Newly Established HTLVI-immortalized 
Rat  T  Cell Lines.  In four  newly  established  HTLV-I-im- 
mortalized rat cell lines,  it was confirmed that  at least one 
full length of HTLV-I provirus genome was integrated, tran- 
Table  1.  Characterization  of HTLV-I-immortalized  Rat Cell Lines 
Human  HTLV-I 
Rat  marker*  marker* 
Provirus  Protein 
Cell line  CD5  CD4  CD8  IL-2R  slg  CD4  slg  genome  mRNA  synthesis~ 
Lewis-S1  +  +  -  +  -  -  -  +  +  + 
F344-$1  +  +  -  +  -  -  -  +  +  + 
WKA-S1  +  +  -  +  -  -  -  +  +  + 
ACI-S1  +  +  -  +  -  -  -  +  ND  + 
* Cell surface markers were detected by indirect immune fluorescence  using FACScan  |  (Becton Dickinson & Co.). Details of antibodies are in Materi- 
als and Methods. 
* HTLV-I gag proteins were detected with an HTLV-specific mAb (Epitope Inc., Beaverton, OR.) by Western  blot analysis. 
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Blots analyses,  respectively. Analyses of cell surface markers 
showed these cell lines to be positive for rat CD4 and CD5, 
and to be negative for rat CD8 and human markers.  They 
also expressed the rat IL-2 receptor. The results are summa- 
rized  in  Table  1.  Morphologically,  nuclear  polymorphism 
resembling ATL cells was seen in a large proportion of WKA- 
$1 and ACI-SI cells. The other cell lines also contained cells 
with nuclear polymorphism,  albeit to a lesser extent.  Only 
in the ACI-S1 cell line were extracellular type C virus parti- 
cles sometimes evident,  as  seen electron microscopically. 
Infectious Transmission of HTLV-I into Newborn and Adult 
Rats.  Lewis-S1 and WKA-S1 cells were injected into new- 
born LEW and WKA rats. Purified DNA from PBMC was 
subjected to  PCR  amplification,  using  both  pol  and  pX 
primers. Samples in which PCR results were positive for both 
pol  and  pX  primers  were considered  to  be positive.  The 
HTLV-I provirus genome was evident in PBMC from 16 of 
18 LEW rats,  and all of three WKA rats at 4-6 mo after 
birth (Table 2). We considered that Lewis-S1  and WKA-S1 
cells produced HTLV-I virus and had infectivity potential for 
the newborn rats, however, antibodies against HTLV-I were 
never detected in these rats at 1-7 mo after birth. When MT-2 
cells were injected into newborn LEW,  WKA,  F344,  and 
ACI rats, the HTLV-I provirus genome was detected in PBMC 
from all of eight LEW rats (100%), eight of nine WKA rats 
(89%),  16 of 20 F344 rats (80%),  and seven of eight ACI 
rats (88%).  Only 2 of 16 F344 rats seroconverted for anti- 
HTLV-I antibodies,  the titers being between 1:8 and  1:16. 
None of the other rats had anti-HTLV-I antibodies (Table 2). 
When MTo2 cells were injected intravenously into seven 
different strains of adult rats,  all five (100%) in each strain 
(except for F344,  since only one rat was tested) carried the 
HTLV-I  provirus  genome  in  their  DNA  extracted  from 
PBMCs 4 mo after injection  (Table 3). Anti-HTLV-I  anti- 
bodies were detected in all these rats as early as 3 wk after 
injection, and the titers ranged between 1:8 and 1:8,192 there- 
after.  The specificity of these antibodies against HTLV-I an- 
tigen was confirmed by evidence of HTLV-I-specific gag pro- 
teins  (p19,  p24,  p53),  obtained using Western  Blots (data 
not  shown). 
Humoral Immune Response against HTLV-I.  Humoral an- 
tibody responses against HTLV-I were compared. Adult LEW, 
WKA, F344, ACI, SDJ, BUF, and LEJ rats were given in- 
travenous injections of 107 MT-2 cells,  twice,  as described 
above, and anti-HTLV-I antibodies in the sera were measured 
at 2, 3, 7, 13, 21, 28, 40, and 49 wk after the first injection. 
As shown in Fig.  1, the antibodies were detectable as early 
as 2-3 weeks after the injection,  and a plateau was reached 
at 12 wk. Antibody titers tended to decline slightly after 28 
wk but were high at 49 wk. ACI and SDJ rats were consid- 
ered to be high responders, as the titer of anti-HTLV-I anti- 
bodies was higher than for other strains, and LEW rats were 
low responders, with low anti-HTLV-I antibodies. F344 rats 
produced a high level of anti-HTLV-I antibodies for up to 
13 wk after the first injection. Further measurement of anti- 
HTLV-I antibody was done in only one of F344 rats main- 
taining  a high level of antibody titer of 1:4,096 at 28 wk. 
The F344 strain was thus considered to be a high responder, 
like the ACI and SDJ strains.  Rats of the other three strains 
produced anti-HTLV-I  antibodies with intermediate  titers, 
and were classed as intermediate responders. The difference 
in humoral response against HTLV-I is statistically significant 
(student's  t  test). 
Tissue Distribution of the HTLV-I Provirus Genome.  Five fe- 
male F344 rats injected with MT-2 cells in the neonatal period 
were killed at 50 wk. DNAs extracted from PBMC and tissues 
from each organ were subjected to PCK amplification, using 
pX primers. Each DNA sample was PCK analyzed more than 
twice, and the sample in which the HTLV-I provirus genome 
was reproducibly demonstrated was judged as positive. The 
HTLV-I provirus genome was detected in almost all organs 
examined, including the thymus (5/5), kidney (5/5), spleen 
(4/5), submandibular gland (4/5), lymph nodes (5/5), and 
PBMC (5/5) (Table 4). The PCR result is shown in Fig. 2. 
Development of  HAM/TSP-Iike Myetopathy.  Eight of nine 
WKA  rats  neonatally  inoculated  with  MT-2 cells  became 
HTLV-I carriers yet had no detectable anti-HTLV-I antibodies 
Table  2.  Transmission of HTLV-I into Newborn Rats 
Rat MHC  Cells injected  Anti-HTLV-I  Presence of HTLV-I 
Strain  RT1  n  (107)  antibodies*  provirus  genome* 
LEW  1  18  LEW-S1  0/18  (0%)  16/18 (89%) 
WKA  k  3  WKA-S1  0/3  (0%)  3/3  (100%) 
LEW  1  8  MT-2  0/8  (0%)  8/8 (100%) 
WKA  k  9  MT-2  0/9  (0%)  8/9 (89%) 
F344  Iv1  20  MT-2  2/20 (10%)  16/20 (80%) 
ACI  avl  8  MT-2  0/8  (0%)  7/8 (88%) 
* Anti-HTLV-I antibodies were measured at 1 and 7 mo after birth. 
* Presence of the HTLV-I provirus genome was determined 4--6 mo after birth. 
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Rat  MHC  Age at  first  Anti-HTLV-I  Presence of HTLV-I 
Strain  R.T1  n  MT-2  injection*  antibodies  provirus genome* 
wk 
LEW  1  5  16  5/5  5/5 
WKA  k  5  16  5/5  5/5 
F344  lvl  5  16  5/5  1/1 
ACI  avl  5  16  5/5  5/5 
SDJ  u  5  16  5/5  5/5 
BUF  b  5  16  5/5  5/5 
LEJ  j  5  16  5/5  5/5 
* 107 cells of MT-2 were injected into the tail vein twice at 2-wk intervals. 
t Purified DNA from PBMC was subjected  to PCR amplification  at 4 mo after  injection. 
(Table 2). Four rats were killed at 4 mo, and tissue distribu- 
tion ofprovirus genomes was eaamined. One of the remaining 
four male rats died at 12 mo of unknown causes and an au- 
topsy was not done. At 16 mo, two of three rats were first 
seen to have spastic paraparesis  of the hind legs, and 2 wk 
later, the remaining had similar symptoms. The spastic parapa- 
resis progressed within 3 too, and all three rats could hardly 
move because of the muscular atrophy of the hind legs. A 
most severely affected rat, WKA no.  54, and a moderately 
affected rat,  WKA  no.  57,  were histologically  examined. 
Provirus genomes in the central nervous system (CNS) tissues, 
as well as in the PBMC, and anti-HTLV-I antibodies in the 
serum and CSF, were also examined. The remaining one was 
found dead and an autopsy was not done. Macroscopically, 
the brains of both rats appeared normal.  The spinal cord of 
WKA no. 54 showed slight atrophy, particularly in the tho- 
racic region,  while that  of no.  57 appeared to be normal. 
On microscopic examination of no. 54, both myelin and axons 
in the lateral and anterior funiculi were extensively damaged 
in a symmetrical fashion, and were infiltrated with abundant 
foamy macrophages (Fig. 3, A-D). Marked vacuolar changes 
were observed, however, slight vacuolar changes were also 
observed in the age-matched untreated controls. The lesion 
developed preferentially in the lateral and anterior funiculi, 
and apparently to a lesser extent in the posterior funiculi. 
The most severe lesions were at levels of the thoracic cord, 
where they continued from the cervical to the lumbar cord 
and were localized in the outer portion of the funiculi. The 
schematic distribution of the affected lesion in the spinal cord 
is shown in Fig. 3 E. The inner portion of the funiculi and 
central gray matter appeared intact. Lymphocytic infiltration 
was virtually absent in the white and gray matter, or in the 
perivascular areas throughout  the entire spinal cord. Fibers 
of the anterior  and posterior roots of the severely affected 
cord also showed loss of myelin and axons with infiltration 
of foamy macrophages.  There appeared to be no neuronal 
titre of 
antibod 
12- 
10'  (2n) 
8 
4' 
2- 
o  l  I  I  I  I 
0  10  20  30  40  50 weeks after infection 
J,  *** 
.~~l  F344 (5 
WKA (5) 
LEW (5) 
ACt  (5) 
SDJ  (5) 
BUF  (5) 
=  LEJ  (5) 
Figure 1.  Strain differences in anti-HTLV-I 
antibody production in rats. Results represent 
mean  titer  _+  SD.  Differences  in  response 
against  HTLV-I  are  statistically  significant 
(student's  t  test).  * p  <0.05;  "*  p  <0.01; 
￿9  **  number  of  rats  examined  is  given  in 
parenthesis. 
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Tissues examined 
Submandibular 
Rat no.  Cerebrum Cerebellum Thymus  Heart  Lung  Liver  Kidney Spleen  gland  Lymph nodes  PBMC 
36  -  -  +  -  +  -  +  +  +  +  + 
128  -  -  +  +  +  +  +  +  +  +  + 
129  +  -  +  -  -  +  +  +  -  +  + 
130  +  +  +  +  +  -  +  +  +  +  + 
131  +  -  +  -  -  -  +  -  +  +  + 
degeneration in the anterior horn cells, ceils  of  Clark's column, 
or any nuclei. 
Loss of  myelin or axonal degeneration was not seen in the 
cerebrum, the cerebellum, or the brain stem above the level 
of the medulla oblongata. Perivascular  cufflngs with lympho- 
cytes were not observed. Atypical lymphocytes were absent 
in the brain and spinal cord. Muscle of the hind legs showed 
severe  group atrophy without inflammatory  reaction. Other 
organs were histologically normal. Pathological findings of 
WKA no. 57 were essentially the same as those in no. 54, 
with loss of myelin and axons and infiltration of foamy mac- 
rophages in the hteral and anterior funiculi. Although severity 
of the affected lesions was less pronounced than that of no. 
54, levels of the thoracic cord were preferentially damaged 
(Fig. 3 E). Lymphocytic  infiltration was not observed. Anti- 
HTLV-I antibodies  in the sera of nos. 54 and 57 and CSF 
of no.  54 were negative.  CSF of no.  57 could not be col- 
lected.  The HTLV-I provirus  genome was evident  in  the 
PBMC, cerebrum, and spinal cord of no. 57 by PCR amplifi- 
cation.  The spinal cord of no.  54 was not examined. 
Figure  2.  Tissue  distribution  of the HTLV-I provirus genome,  using 
PCR  and pX primers in F344 rat (no.  130). The positive control is cloned 
Lewis-S1  cells,  and  the  negative control  is  PBMC  of a  normal  rat. 
Discussion 
Several observations presented in this paper lead to the con- 
clusion that the inbred rat provides a useful animal model 
for HTLV-I infection in humans.  In 1984, we reported that 
HTLV-I infected and immortalized rat T cells of the spleen, 
lymph nodes, and thymus, when cocultivated with BrdUrd- 
treated ATL ceils (17). In the present study, by inoculating 
newly established  rat T cell lines or a human T cell line, MT-2, 
we succeeded in establishing HTLV-I carriers in several in- 
bred strains of  newborn and adult rats, as determined  by virus 
genome integration. We found no strain differences in the 
susceptibility to HTLV-I virus infection in neonates, and trans- 
mission efficiency  exceeded  80%. Adult rats of  several  different 
strains are equally susceptible to HTLV-I infection. Newborn 
HTLV-I carriers, in general, show an unresponsiveness in hu- 
moral antibody response to HTLV-I throughout their life span. 
However, this unresponsiveness can be easily broken down, 
since a secondary challenge of MT-2 cells at 7 mo leads to 
the production of  anfi-HTLV-I  antibodies with antibody titers 
of 1:256 to 1:512, as tested 1 mo later (our unpublished results). 
Adult HTLV-I carriers continuously produce humoral anti- 
bodies to HTLV-I similar to those in humans. According io 
antibody titers against HTLV-I, there are three groups of  in- 
bred rat strains: ACI, F344, and SDJ (high responders); WKA, 
BUF,  and LEJ (intermediate  responders);  and LEW  (low 
responders).  In  human  carriers,  there  are  high  and  low 
responders to HTLV-I; as it is possibly related to particular 
HLA haplotypes, the former is likely to beaome HAM/TSP 
(27). Therefore, strain difference in the humoral antibody re- 
sponse to HTLV-I in the rat provides useful information for 
future research. 
Three of three newborn HTLV-I carriers of the WKA strain 
developed  spastic  paraparesis of  the hind legs, at 16 too. Clinical 
symptoms and neuropathological  findings generally mimic 
those of HAM/TSP seen in humans (6-9, 28-30).  The le- 
sions are primarily confined to the lateral and anterior funiculi 
of the spinal cord. The most severe lesions are levels of the 
thoracic cord, and continue from the cervical to the lumbar 
cord. Both myelin and axons are extensively damaged, in a 
symmetrical fashion, and are infiltrated with massive foamy 
macrophages.  Newborn and adult carriers of other strains 
985  Ishiguro  et  al. Figure 3.  Histopathological  findings and schematic distribution of the affected lesion in the spinal cord of HAM rats. (A and B) Symmetrical distribu- 
tion of the damage in the white matter is shown, as a whole view of the affected thoracic cord (no. 54, Th7) (x 30). (C and D) Vacuolar degeneration, 
demyelination, and infiltration of foamy macrophages  are evident in the enclosed area of A  (x 140). Distribution of affected lesions in spinal cords 
of nos.  54 and 57 are represented  in the schematic  figure (E). The solid area shows  severe damage and the hatched area a lesser degree of damage. 
No marked change was found in the blank area,  as compared with age-matched untreated control. (A and C) HE  stain;  (B and D) LFB stain. 
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logically. Thus, HTLV-I carriers of the WKA strain are suit- 
able models for the HAM/TSP in humans. The WKAH/Hkm 
rats, formerly called Wistar-King-Aptekman rats, are agouti 
(A/A), coat color (B/B), and albino (c/c), and have been typed 
for the following polymorphic loci: Akp-1 ~, AII~,  Cs b, Es- 
1 o, Es-2  ~, Es-3  ~, Es.4 b, Es-7 b, Es-8 s, Es.9  ~, Es-lO  ~, Essi  b, Fh.1 b, 
Gst-1 b, Hao-1 ~ Hbb ~, Mdl-I ~, Pgd  b, RTI k, Svp-I a,  Tam-1  b (31, 
32). Since HAM/TSP occurs with increased frequency with 
certain HLA  haplotypes (27),  the genetic background of 
WKA, especially the RT/k haplotype of rat MHC, may be 
one of critical host factors determining disease susceptibility. 
Further investigations are necessary to clarify  this point. 
Retrovirus-induced neurological diseases have been recog- 
nized for many years in animals. Among them, retroviral spon- 
giform polioencephalomyelopathy  in wild mice (33-35) and 
visna in sheep (36-38) have been most extensively studied. 
From animal studies, there is evidence that retroviral infec- 
tion can damage the CNS tissue via either immunological 
mechanisms or through a direct neurotropic effect of the 
retrovirus. The intense lymphocytic infiltration in the affected 
lesion and perivascular areas of the spinal cord, the presence 
of IgG and IgM oligoclonal bands in the CSF, some of which 
are directed against HTLV-I, the high titer of antibodies to 
HTLV-I, and the therapeutic effectiveness  of high-dose steroids 
are all consistent with an immune hypothesis of the CNS 
tissue damage in HAM/TSP (7-9,  28-30).  However, the 
mechanism of CNS tissue damage in HAM/TSP still remains 
virtually unknown. There are at least three essential points 
to stress about these diseased rats,  tentatively designated as 
"HAM rats" First, HAM rats produce no detectable anti- 
bodies to HTLV-I in the CSF or in the serum. As already 
mentioned, HAM/TSP patients are usually associated with 
high-titered antibodies to HTLV-I in both the CSF and serum 
(7, 9). Humoral antibody response to HTLV-I may not play 
a major role,  if any, in the pathogenesis of HAM-TSP in 
humans. Production of humoral antibodies to HTLV-I in the 
CNS of HAM/TPS patients might be a stir-protecting reac- 
tion or merely a secondary phenomenon. Second, in con- 
trast to the affected spinal cord in HAM/TSP patients (28-30), 
HAM rats show no lymphocytic infiltration in the white or 
gray matter, or in the perivascular areas throughout the whole 
spinal cord. Foamy macrophages predominantly infiltrate the 
affected lesion. Visna is a slow retrovirus infection of sheep 
that produces both inflammatory and demyelinating lesions 
of the CNS. Although the pathogenesis of the CNS lesions 
is still unclear,  host factors in virus susceptibility and im- 
mune mechanisms undoubtedly play pathogenic roles (37--41). 
Sheep experimentally infected by intracerebral inoculation of 
visna virus are apparently healthy, but at autopsy many show 
an inflammatory exudate throughout the CNS and meninges 
within weeks (37). In the spinal cord, there is a marked histo- 
logical difference between the affected lesions of the early and 
advanced stages of the disease (42).  At an early stage,  the 
main pathological changes are inflammatory reactions con- 
sisting oflymphocytes, macrophages, and some plasma cells. 
In advanced lesions, demyelinating  foci closely associated with 
clinical paresis occur and inflammation is minimal or absent. 
Since the initial stage of rat HAM has not been examined, 
it is too early to conclude with certainty that lack of lym- 
phocytic infiltration in the affected lesions is a characteristic 
pathologic feature of rat HAM. Whether the absence of lym- 
phocytic infiltration in the affected lesion reflects the stage 
of the disease process, species difference in the host response 
between rats and humans, or nonimmunological  demyelina- 
tion in the pathogenesis of rat HAM remains to be deter- 
mined. Third, HTLV-I provirus genome was dearly demon- 
strated by PCR in the spinal cord and cerebrum as well as 
PBMC of a HAM rat no. 57.  The precise localization of 
provirus genome, whether it localizes in the damaged spinal 
cord tissue, in the infiltrating macrophages, or in the blood- 
borne or hidden lymphocytes carrying HTLV-I, will remain 
to be determined. Neither integration of provirus genome, 
nor expression of mKNA and viral proteins of HTLV-I, has 
been confirmed in the diseased CNS tissues of HAM/TSP 
patients (29, 43). Therefore, there is no direct proof that the 
inflammation  and  tissue  damage  in  the  spinal  cord  of 
HAM/TSP patients is a consequence of viral infection in the 
CNS tissue. Determination of in situ localization of provirus 
genome, mRNA, and viral proteins in the affected spinal cord 
of the HAM rat would be of critical importance for inves- 
tigating pathogenic roles of HTLV-I in the disease mecha- 
nism of HAM/TSP in humans. 
In conclusion, this is the first description of a rat model 
for HAM/TSP in humans. This model is expected to con- 
tribute to a better understanding of mechanisms involved in 
the etiopathogenesis of HTLV-I-related  immunological dis- 
eases in humans, particularly HAM/TSP. 
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